Pharma company Lupin Limited has announced the launch of its Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

The tablets, 5 mg, 20 mg and 40 mg are the AB rated generic equivalent of Daiichi Sankyo Inc.’s Benicar tablets and indicated for the treatment of hypertension, alone or in combination with other antihypertensive agents, to lower blood pressure.

Benicar tablets had US sales of USD 681 million (IMS MAT July 2017).